Biosight is a clinical-stage hemato-oncology company developing innovative therapeutics which address significant unmet needs and large markets.

Biosight’s lead product, aspacytarabine (BST-236), is a novel antimetabolite, which provides the benefit of intensive chemotherapy while avoiding much of the toxicity associated with it.

Cumulative clinical data, recently presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, suggest that aspacytarabine is safe and efficacious as a first-line therapy for patients who are unfit for intensive chemotherapy.


Aspacytarabine is uniquely positioned to serve as a superior backbone for AML and MDS therapy, either as a single-agent or in combination with other agents

Aspacytarabine positioning.png